

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM739829

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Release of Security Interest in Certain Intellectual Property		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Oxford Finance LLC		07/08/2022	Limited Liability Company: DELAWARE
RECEIVING PARTY DATA			
Name:	Kala Pharmaceuticals, Inc.		
Street Address:	1167 Massachusetts Ave.		
City:	Arlington		
State/Country:	MASSACHUSETTS		
Postal Code:	02476		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 11			
Property Type	Number	Word Mark	
Registration Number:	5722929	INVELTYS	
Registration Number:	6301667	EYSUVIS	
Registration Number:	5968321	INVELTYS	
Registration Number:	5968322	INVELTYS	
Registration Number:	5968323	V	
Registration Number:	5968324	V	
Registration Number:	5951075	AMPPLIFY	
Registration Number:	6310079	EYSUVIS	
Registration Number:	6310078	EYSUVIS	
Serial Number:	90126587	EYSUVIS	
Serial Number:	90126591	EYSUVIS	
CORRESPONDENCE DATA			
Fax Number:	2128366337		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	12128367319		
Email:	paul.somelofske@arnoldporter.com		
Correspondent Name:	Paul J. Somelofske		
Address Line 1:	c/o Arnold & Porter Kaye Scholer LLP		

OP \$290.00 5722929

Address Line 2: 250 West 55th Street
Address Line 4: New York, NEW YORK 10019-9710

NAME OF SUBMITTER: Paul J. Somelofske

SIGNATURE: /Paul J. Somelofske/

DATE SIGNED: 07/08/2022

Total Attachments: 26

source=65989664_v 3_Oxford (Kala) - Partial IP Release (Executed) (002)#page1.tif
source=65989664_v 3_Oxford (Kala) - Partial IP Release (Executed) (002)#page2.tif
source=65989664_v 3_Oxford (Kala) - Partial IP Release (Executed) (002)#page3.tif
source=65989664_v 3_Oxford (Kala) - Partial IP Release (Executed) (002)#page4.tif
source=65989664_v 3_Oxford (Kala) - Partial IP Release (Executed) (002)#page5.tif
source=65989664_v 3_Oxford (Kala) - Partial IP Release (Executed) (002)#page6.tif
source=65989664_v 3_Oxford (Kala) - Partial IP Release (Executed) (002)#page7.tif
source=65989664_v 3_Oxford (Kala) - Partial IP Release (Executed) (002)#page8.tif
source=65989664_v 3_Oxford (Kala) - Partial IP Release (Executed) (002)#page9.tif
source=65989664_v 3_Oxford (Kala) - Partial IP Release (Executed) (002)#page10.tif
source=65989664_v 3_Oxford (Kala) - Partial IP Release (Executed) (002)#page11.tif
source=65989664_v 3_Oxford (Kala) - Partial IP Release (Executed) (002)#page12.tif
source=65989664_v 3_Oxford (Kala) - Partial IP Release (Executed) (002)#page13.tif
source=65989664_v 3_Oxford (Kala) - Partial IP Release (Executed) (002)#page14.tif
source=65989664_v 3_Oxford (Kala) - Partial IP Release (Executed) (002)#page15.tif
source=65989664_v 3_Oxford (Kala) - Partial IP Release (Executed) (002)#page16.tif
source=65989664_v 3_Oxford (Kala) - Partial IP Release (Executed) (002)#page17.tif
source=65989664_v 3_Oxford (Kala) - Partial IP Release (Executed) (002)#page18.tif
source=65989664_v 3_Oxford (Kala) - Partial IP Release (Executed) (002)#page19.tif
source=65989664_v 3_Oxford (Kala) - Partial IP Release (Executed) (002)#page20.tif
source=65989664_v 3_Oxford (Kala) - Partial IP Release (Executed) (002)#page21.tif
source=65989664_v 3_Oxford (Kala) - Partial IP Release (Executed) (002)#page22.tif
source=65989664_v 3_Oxford (Kala) - Partial IP Release (Executed) (002)#page23.tif
source=65989664_v 3_Oxford (Kala) - Partial IP Release (Executed) (002)#page24.tif
source=65989664_v 3_Oxford (Kala) - Partial IP Release (Executed) (002)#page25.tif
source=65989664_v 3_Oxford (Kala) - Partial IP Release (Executed) (002)#page26.tif

RELEASE OF SECURITY INTEREST IN CERTAIN INTELLECTUAL PROPERTY

This RELEASE OF SECURITY INTEREST IN CERTAIN INTELLECTUAL PROPERTY (this “Release”), dated as of July 8, 2022 (the “Effective Date”), is made by Oxford Finance LLC, in its capacity as collateral agent (the “Collateral Agent”) for itself and the Lenders, in favor of Kala Pharmaceuticals, Inc., a Delaware corporation (the “Grantor”).

WHEREAS, pursuant to that certain Loan and Security Agreement, dated as of May 4, 2021, by and among the Collateral Agent, the Lenders from time to time party thereto and the Grantor (as amended, supplemented or otherwise modified from time to time, the “Loan Agreement”), the Grantor granted to the Collateral Agent for the benefit of the Lenders a security interest in and to certain collateral;

WHEREAS, pursuant to the Loan Agreement, the Grantor executed and delivered for recordation with the United States Patent and Trademark Office (the “USPTO”) an Intellectual Property Security Agreement, dated as of May 4, 2021 (the “IP Security Agreement”);

WHEREAS, the IP Security Agreement was recorded with the USPTO (i) in respect of Patents, on May 6, 2021 at Reel/Frame 056168/0602 and (ii) in respect of Trademarks, on May 6, 2021 at Reel/Frame 007282/0798 and

WHEREAS, the Collateral Agent has agreed to release, discharge, terminate and cancel its security interest in certain specified Intellectual Property Collateral as provided for in this Release.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Collateral Agent hereby agrees as follows:

1. Defined Terms. All capitalized terms used, but not otherwise defined herein, shall have the respective meanings ascribed in or otherwise referenced in the Loan Agreement or the IP Security Agreement, as applicable.
2. Release. The Collateral Agent, without representation, warranty or recourse of any kind, hereby releases, discharges, terminates and cancels all of its security interest and liens of any kind, nature or description it or any Lender holds, whenever and however arising, pursuant to the IP Security Agreement in and to the following (the “Released Collateral”):
 - a. all Patents forth in Schedule A hereto;
 - b. all Trademarks forth in Schedule B hereto; and
 - c. any and all claims for damages by way of past, present and future infringement of any of the foregoing, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the Patent and Trademark rights identified above.

If and to the extent that the Collateral Agent has acquired any right, title or interest in and to the Released Collateral under the IP Security Agreement, the Collateral Agent, without representation, warranty or recourse of any kind, hereby transfers, conveys and assigns such right, title or interest to the Grantor. This Release is applicable only and solely with respect to the Released Collateral and to no other collateral arising under the Loan Agreement or the IP Security Agreement. The Collateral Agent retains all security interests, liens, rights, titles and


interests pledged and granted to the Collateral Agent under the Loan Agreement and the IP Security Agreement with respect to all such other collateral, and the Collateral Agent's security interest, liens, rights, titles and interests in such other collateral shall not, and shall not be deemed to, be impaired, interrupted or otherwise modified in any respect by this Release.

3. Further Assurances. The Collateral Agent agrees to take all further actions, and provide to the Grantor and its successors, assigns or other legal representatives, all such cooperation and assistance (including, without limitation, the execution and delivery of any and all documents or other instruments), reasonably requested by the Grantor, at the Grantor's sole cost and expense, to more fully and effectively effectuate the purposes of this Release.
4. Recordation. The Collateral Agent authorizes the Grantor or its designee to file this Release for recordation with the USPTO, and the Grantor authorizes and requests that the Commissioner for Patents, the Commissioner for Trademarks and any other applicable government officer record this Release.
5. Collateral Agent. In carrying out its responsibilities hereunder, the Collateral Agent shall have all of the rights, powers, privileges, protections, duties, indemnities, and immunities which the Collateral Agent possesses in such capacity under the Loan Agreement.
6. Execution in Counterparts. This Release may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one agreement.
7. Governing Law. This Release shall be governed exclusively under the laws of the State of New York, without regard to principles of conflicts of law.

[Signature Page Follows]

IN WITNESS WHEREOF, the Collateral Agent and the Grantor have caused this Release to be duly executed by its officers thereunto duly authorized as of the first date written above.

OXFORD FINANCE LLC, as Collateral Agent

By: 
Name: Colette H. Featherly
Title: Senior Vice President

KALA PHARMACEUTICALS, INC., as Grantor

By: _____
Name: Mary Reumuth
Title: Chief Financial Officer

[Signature Page to Release of Security Interest in Certain Intellectual Property]


TRADEMARK
REEL: 007773 FRAME: 0899

IN WITNESS WHEREOF, the Collateral Agent and the Grantor have caused this Release to be duly executed by its officers thereunto duly authorized as of the first date written above.

OXFORD FINANCE LLC, as Collateral Agent

By: _____
Name: Colette H. Featherly
Title: Senior Vice President

KALA PHARMACEUTICALS, INC., as Grantor

By:  _____
Name: Mary Reumuth
Title: Chief Financial Officer

SCHEDULE A

Patents

[See attached.]

PATENT FAMILY: KP002

TITLE(S): COMPOSITIONS AND METHODS UTILIZING POLYVINYL ALCOHOL AND/OR OTHER POLYMERS THAT AID PARTICLE

TRANSPORT IN MUCUS

INVENTOR(S): POPOV, Alexey

KALA REF #	COUNTRY	APPL'N NO.	FILING DATE	PUB #	PATENT #	EXP. DATE	STATUS
KP002.A/PR	US	61642,261	5/3/2012				EXPIRED
KP002.B/WO	WO	PCT/US2013/039499	5/3/2013	WO2013/166408			EXPIRED
KP002.B/US	US	13886,514	5/3/2013	US2013/0316009	US10,668,041	7/20/2033	GRANTED
KP002.B/US2	US	16,883,778	5/26/2020	US2020/0289405	US11,318,088	7/20/2033	GRANTED
KP002.B/US3	US	177708,960	3/30/2022				PENDING
KP002.B/AU	AU	2013256064	5/3/2013		AU2013256064	5/3/2033	GRANTED
KP002.B/AU2	AU	2018202074	5/3/2013		AU2018202074	5/3/2033	GRANTED
KP002.B/AU3	AU	2020201184	5/3/2013		AU2020201184	5/3/2033	GRANTED
KP002.B/CA	CA	2,871,745	5/3/2013			5/3/2033	PENDING
KP002.B/EP	EP	13723350,8	5/3/2013	EP2844227	EP2844227	5/3/2033	COMPLETED
KP002.B/EP-DE	DE				DE602013074111,5	5/3/2033	GRANTED
KP002.B/EP-FR	FR				EP2844227	5/3/2033	GRANTED
KP002.B/EP-GB	GB				EP2844227	5/3/2033	GRANTED
KP002.B/EP2	EP	20208225,1	5/3/2013	EP3808339		5/3/2033	PENDING
KP002.B/HK-EP	HK-EP	15108778,4	5/3/2013		HK1208160	5/3/2033	GRANTED
KP002.B/HK-EP2	EP-HK	42021039620	5/3/2013	HK40049934		5/3/2033	PENDING
KP002.B/JP	JP	2015-510486	5/3/2013	JP2015-515990A	JP6360040	5/3/2033	GRANTED
KP002.B/JP2	JP	2018-117609	5/3/2013		JP6816084	5/3/2033	GRANTED
KP002.B/JP3	JP	2020-144057	5/3/2013				ABANDONED
KP002.B/JP4	JP	2021-185415	5/3/2013			5/3/2033	PENDING
KP002.B/KR	KR	10-2014-7033575	5/3/2013	KR10-2015-004909A	KR10-2154880	5/3/2033	GRANTED

PATENT FAMILY: KP003

TITLE(S): US: NANOCRYSTALS, COMPOSITION AND METHODS THAT AID PARTICLE TRANSPORT IN MUCUS

INVENTOR(S): POPOV, Alexey; ENLOW, Elizabeth M.; BOURASSA, James; GARDNER, Colin; CHEN, Hongming; ENSIGN, Laura M.; LAI,

Samuel K.; YU, Tao; HANES, Justin; YANG, Ming

KALA REF #	COUNTRY	APPL'N NO.	FILING DATE	PUB #	PATENT #	EXP. DATE	STATUS
------------	---------	------------	-------------	-------	----------	-----------	--------

KP003.A/PR	US	61/642,227	5/3/2012					EXPIRED
KP003.B/WO	WO	PCT/US2013/039467	5/3/2013	WO2013/166385				EXPIRED
KP003.B/US	US	13/886,493	5/3/2013		US9,056,057		5/3/2033	GRANTED
KP003.B/US2	US	14/731,972	6/5/2015		US9,393,213		5/3/2033	GRANTED
KP003.B/US3	US	14/731,921	6/5/2015		US9,393,212		5/3/2033	GRANTED
KP003.B/US4	US	15/187,552	6/20/2016		US9,532,955		5/3/2033	GRANTED
KP003.B/US5	US	15/354,704	11/17/2016		US9,737,491		5/3/2033	GRANTED
KP003.B/US6	US	15/616,799	6/7/2017		US10,058,511		5/3/2033	GRANTED
KP003.B/US7	US	15/976,736	5/10/2018		US10,736,854		5/3/2033	GRANTED
KP003.B/US8	US	16/923,980	7/8/2020	US2021/0128483				PENDING
KP003.B/AU	AU	2013/256130	5/3/2013		AU2013256130		5/3/2033	GRANTED
KP003.B/AU2	AU	2018/201772	5/3/2013		AU2018201772		5/3/2033	GRANTED
KP003.B/AU3	AU	2020/203213	5/3/2013				5/3/2033	ALLOWED
KP003.B/CA	CA	2,871,778	5/3/2013				5/3/2033	ALLOWED
KP003.B/EP	EP	13724670.8	5/3/2013	EP2844295				WITHDRAW
KP003.B/EP2	EP	22150254.5	5/3/2013					PENDING
KP003.B/HK-EP	HK	1510878	5/3/2013					ABANDONED
KP003.B/JP	JP	2015-510480	5/3/2013		JP6360039		5/3/2033	GRANTED
KP003.B/JP2	JP	2018-117644	5/3/2013		JP6816065		5/3/2033	GRANTED
KP003.B/JP3	JP	2020-152328	5/3/2013					ABANDONED
KP003.B/JP4	JP	2021-185416	5/3/2013					PENDING
KP003.B/KR	KR	10-2014-7033571	5/3/2013	KR2015-0006868	KR-2140989		5/3/2033	GRANTED
KP003.B/KR2	KR	10-2020-7022063	5/3/2013		KR10-2310775		5/3/2033	GRANTED

PATENT FAMILY: KP004

TITLE(S): PHARMACEUTICAL NANOPARTICLES SHOWING IMPROVED MUCOSAL TRANSPORT
 INVENTOR(S): POPOV, Alexey, ENLOW, Elizabeth M., CHEN, Hongming, BOURASSA, James

KALA REF #	COUNTRY	APPLN NO.	FILING DATE	PUB #	PATENT #	EXP DATE	STATUS	
KP004.A/PR	US	61/642,261	5/3/2012				EXPIRED	
KP004.A/PR2	US	61/642,313	5/3/2012				EXPIRED	
KP004.B/PR	US	61/738,949	12/18/2012				EXPIRED	
KP004.C/PR	US	61/784,701	3/14/2013				EXPIRED	
KP004.D/WO	WO	PCT/US2013/039540	5/3/2013	WO2013/166436			EXPIRED	
KP004.D/US1	US	13/886,605	5/3/2013	US2013/0316006			ABANDONED	
KP004.D/US2	US	13/886,658	5/3/2013	US2013/0316001			ABANDONED	
KP004.D/US2	US	15/992,494	5/30/2018	US2018/0271782			ABANDONED	
KP004.D/US4	US	16/945,398	7/31/2020	US2021/0052489			PENDING	
KP004.D/AU	AU	2013/256092	5/3/2013		AU2013256092		5/3/2033	GRANTED
KP004.D/AU2	AU	2018/201215	5/3/2013		AU2018201215		5/3/2033	GRANTED
KP004.D/AU3	AU	2020/203052	5/3/2013				5/3/2033	PENDING
KP004.D/BR	BR	BR1120140272964	5/3/2013				5/3/2033	PENDING
KP004.D/CA	CA	2,871,748	5/3/2013		CA2871748		5/3/2033	GRANTED
KP004.D/CL	CL	2014-2956	5/3/2013		CL59,839		5/3/2033	GRANTED
KP004.D/CL2	CL	3433-2019	5/3/2013				5/3/2033	PENDING



KP004.D/CL3	CL	3432-2019	5/3/2013				5/3/2033	PENDING
KP004.D/CN	CN	201380035493-6	5/3/2013				5/3/2033	ABANDONED
KP004.D/CN2	CN	202010551315-0	5/3/2013	CN111714472			5/3/2033	PENDING
KP004.D/CN3	CN	202010551316-5	5/3/2013	CN111700878			5/3/2033	PENDING
KP004.D/CN4	CN	202010551329-2	5/3/2013	CN111700879			5/3/2033	PENDING
KP004.D/CN5	CN	202010551342-8	5/3/2013	CN111700880			5/3/2033	PENDING
KP004.D/EP	EP	13723629.5	5/3/2013	EP2844223			5/3/2033	PENDING
KP004.D/HK-EP	HK-EP	15108779.3	5/3/2013				5/3/2033	PENDING
KP004.D/HK-CN	EP-CN	15109260.7	5/3/2013				5/3/2033	ABANDONED
KP004.D/HK-CN2	EP-CN	42021028083	5/3/2013	HK40037907			5/3/2033	PENDING
KP004.D/HK-CN3	EP-CN	42021027920	5/3/2013	HK40038231			5/3/2033	PENDING
KP004.D/HK-CN4	EP-CN	42021027920	5/3/2013	HK40038232			5/3/2033	PENDING
KP004.D/HK-CN5	EP-CN	42021027921	5/3/2013	HK40038233			5/3/2033	PENDING
KP004.D/JP	JP	2015-510490	5/3/2013		JP6720443		5/3/2033	GRANTED
KP004.D/JP2	JP	2019-182856	5/3/2013				5/3/2033	ABANDONED
KP004.D/JP3	JP	2020-193338	5/3/2013				5/3/2033	PENDING
KP004.D/KR	KR	10-2014-7033577	5/3/2013				5/3/2033	ABANDONED
KP004.D/KR2	KR	10-2021-7002733	5/3/2013				5/3/2033	ALLOWED
KP004.D/MX	MX	MX/a/2014/013315	5/3/2013		MX373352		5/3/2033	GRANTED
KP004.D/MX2	MX	MX/a/2020/007227	5/3/2013	MX/a/2020/007227			5/3/2033	PENDING
KP004.D/NZ	NZ	700875	5/3/2013		NZ700875		5/3/2033	GRANTED
KP004.D/NZ2	NZ	728721	1/31/2017		NZ728721		5/3/2033	GRANTED
KP004.D/NZ3	NZ	733080	6/21/2017		NZ733080		5/3/2033	GRANTED
KP004.D/NZ4	NZ	741873	4/23/2018		NZ741873		5/3/2033	GRANTED
KP004.D/NZ5	NZ	742004	4/27/2018		NZ742004		5/3/2033	GRANTED
KP004.D/NZ6	NZ	742005	4/27/2018		NZ742005		5/3/2033	GRANTED
KP004.D/TH	TH	1401006565	5/3/2013				5/3/2033	PENDING
KP004.E/MO	WO	PCT/US2014/063373	10/31/2014	WO2015/066444			5/3/2033	EXPIRED
KP004.E/US	US	140/70.506	11/2/2013	US2015/0125539	US9.827.191		5/3/2033	GRANTED
KP004.E/US2	US	15808.746	11/9/2017	US2018/0064641	US10.688.045		5/3/2033	GRANTED
KP004.E/US3	US	15977.911	5/11/2018	US2018/0280290	US10.646.436		5/3/2033	GRANTED
KP004.E/US4	US	16888.371	5/29/2020	US2020/0289409	US10.940.108		5/3/2033	GRANTED
KP004.E/US5	US	15977.940	5/11/2018	US2018/0256497	US10.646.437		5/3/2033	GRANTED
KP004.E/US6	US	16221.253	12/14/2018	US2019/0125758	US10.864.219		5/3/2033	GRANTED
KP004.E/US7	US	16896.007	6/8/2020	US2020/0297624	US10.857.096		5/3/2033	GRANTED
KP004.E/US8	US	16988.459	8/7/2020	US2020/0368154	US10.945.948		5/3/2033	GRANTED
KP004.E/US9	US	16988.470	8/7/2020	US2020/0368155	US10.993.908		5/3/2033	GRANTED
KP004.E/US10	US	171170.701	2/8/2021	US2021/0386661				PENDING
KP004.E/US11	US	17207.442	3/19/2021	US2021/0228481	US11.219.596		5/3/2033	GRANTED
KP004.E/US13	US	17207.467	3/19/2021	US2021/0228482	US11.219.597		5/3/2033	GRANTED
KP004.E/AU	AU	2014342097	10/31/2014		AU2014342097		11/2/2033	GRANTED



KP004/E/CA	CA	2928969	10/31/2014		CA2928969	11/2/2033	GRANTED
KP004/E/CA2	CA	3135978	10/31/2014			11/2/2033	PENDING
KP004/E/CN	CN	201480071942.7	10/31/2014		ZL201480071942.7	11/2/2033	GRANTED
KP004/E/CN2	CN	202010578302.2	10/31/2014	CN117743878		11/2/2033	PENDING
KP004/E/CN3	CN	202010578480.5	10/31/2014	CN11743879		11/2/2033	PENDING
KP004/E/EP	EP	14858272.9	10/31/2014	3062796		11/2/2033	PENDING
KP004/E/HK-EP	HK-EP	17100086.6	10/31/2014			11/2/2033	PENDING
KP004/E/HK-CN	HK-CN	17100500.4	10/31/2014		HK1226949	11/2/2033	GRANTED
KP004/E/HK-CN2	HK-CN	42021028764	10/31/2014	HK40039406		11/2/2033	PENDING
KP004/E/HK-CN3	HK-CN	42021028765	10/31/2014	HK40039407		11/2/2033	PENDING
KP004/E/IN	IN	201617014248	10/31/2014		IN359759	11/2/2033	GRANTED
KP004/E/IN2	IN	202018056794	10/31/2014				ABANDONED
KP004/E/JP	JP	2016-552253	10/31/2014		JP6751669	11/2/2033	GRANTED
KP004/E/JP2	JP	2019-219516	10/31/2014		JP6978096	11/2/2033	GRANTED
KP004/E/JP3	JP	2021-179975	10/31/2014			11/2/2033	PENDING
KP004/E/MX	MX	MX/a/2016/005710	10/31/2014		MX384021	11/2/2033	GRANTED
KP004/E/MX2	MX	MX/a/2021/007794	10/31/2014	MX/a/2021/007794		11/2/2033	PENDING
KP004/E/NZ	NZ	719182	10/31/2014				ABANDONED



SCHEDULE B


Trademarks



[See attached.]



Mark	Image	Country	Owner Name	Application #	File Date	Registration #	Registration Date	Description Combined	Status
EYSUVVIS		AUSTRALIA	Seller	1927808	5/18/2018	1927808	8/29/2018	005 - Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for the treatment of dryness of the eye	REGISTERED
INVELTYS		CANADA	Seller	1873402	12/15/2017	TMA1067229	12/23/2019	N/A - Topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for post-surgical treatment of the eye	REGISTERED



Mark	Image	Country	Owner Name	Application #	File Date	Registration #	Registration Date	Description Combined	Status
EYSUVIS		CANADA	Seller	1899974	5/18/2018	TMA1080021	6/25/2020	N/A - Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for the treatment of dryness of the eye	REGISTERED
EYSUVIS		CHINA	Seller	31025579	5/21/2018	31025579	4/13/2019	005 - Ophthalmic pharmaceutical products; eye drops; ophthalmic pharmaceutical preparations; eye-wash; medical collyrium	REGISTERED


Mark	Image	Country	Owner Name	Application #	File Date	Registration #	Registration Date	Description Combined	Status
INVELTYS		CHINA	Seller	45900515	4/29/2020	45900515	12/21/2020	Ophthalmological preparations; ophthalmic preparations; eye drops; medical preparation for eye or intraocular surgery; ophthalmic drug products; collyrium; corn remedies; medicated eye-washes; pharmaceutical preparations	REGISTERED
INVELTYS		EUROPEAN UNION (EUTM)	Seller	017603739	12/15/2017	017603739	3/8/2019	005 - Topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for post-surgical treatment of the eye.	REGISTERED


Mark	Image	Country	Owner Name	Application #	File Date	Registration #	Registration Date	Description Combined	Status
EYSUVIS		EUROPEAN UNION (EUTM)	Seller	017902993	5/18/2018	017902993	9/25/2018	005 - Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for the treatment of dryness of the eye	REGISTERED
EYSUVIS		JAPAN	Seller	2018-66101	5/21/2018	6088912	10/12/2018	005 - Designated goods: Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for the treatment of dryness of the eye	REGISTERED

Mark	Image	Country	Owner Name	Application #	File Date	Registration #	Registration Date	Description Combined	Status
INVELTYYS		MEXICO	Seller	1986895	12/15/2017	1860084	12/15/2017	005 - Topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for post-surgical treatment of the eye	REGISTERED
EYSUVIS		MEXICO	Seller	2650540	11/19/2021			005 - Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for the relief of the signs and symptoms of dry eye disease.	PENDING


Mark	Image	Country	Owner Name	Application #	File Date	Registration #	Registration Date	Description Combined	Status
EYSUVIS		SOUTH KOREA	Seller	40-2018-67794	5/18/2018	40-1457280	3/12/2019	005 - Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for the treatment of dryness of the eye	REGISTERED
EYSUVIS		SWITZERLAND	Seller	78781/2018	9/18/2018	727020	2/6/2019	005 - Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for the treatment of dryness of the eye	REGISTERED


Mark	Image	Country	Owner Name	Application #	File Date	Registration #	Registration Date	Description Combined	Status
INVELTYYS		UNITED KINGDOM	Seller	UK00917603739	12/15/2017	UK00917603739	3/8/2019	005 - Topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for post-surgical treatment of the eye.	REGISTERED
EYSUVIS		UNITED KINGDOM	Seller	UK00917902993	5/18/2018	UK00917902993	9/25/2018	005 - Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for the treatment of dryness of the eye	REGISTERED


Mark	Image	Country	Owner Name	Application #	File Date	Registration #	Registration Date	Description Combined	Status
EYSUVIS		UNITED KINGDOM	Seller	UK00003311937	5/18/2018	UK00003311937	8/17/2018	005 - Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for the treatment of dryness of the eye	REGISTERED
INVELTYS		UNITED STATES	Seller	87/492,686	6/16/2017	5,722,929	4/9/2019	005 - Topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for post-surgical treatment of the eye	REGISTERED



Mark	Image	Country	Owner Name	Application #	File Date	Registration #	Registration Date	Description Combined	Status
EYSUVIS		UNITED STATES	Seller	87/694,659	11/22/2017	6,301,667	3/23/2021	005 - Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for the treatment of dryness of the eye	REGISTERED



Mark	Image	Country	Owner Name	Application #	File Date	Registration #	Registration Date	Description Combined	Status
INVELTYS & Eye Design	INVELTYS	UNITED STATES	Seller	88/018,617	6/28/2018	5,968,321	1/21/2020	005 - Pharmaceuticals preparations and substances for the treatment of inflammation and pain; pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for post-surgical treatment of the eye	REGISTERED


Mark	Image	Country	Owner Name	Application #	File Date	Registration #	Registration Date	Description Combined	Status
INVELTYS & Green Eye Design		UNITED STATES	Seller	88/018,623	6/28/2018	5,968,322	1/21/2020	005 - Pharmaceuticals preparations and substances; pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for post-surgical treatment of the eye	REGISTERED

Mark	Image	Country	Owner Name	Application #	File Date	Registration #	Registration Date	Description Combined	Status
V & Eye Design		UNITED STATES	Seller	88/018,626	6/28/2018	5,968,323	1/21/2020	005 - Pharmaceuticals preparations and substances for the treatment of inflammation and pain; pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for post-surgical treatment of the eye	REGISTERED

Mark	Image	Country	Owner Name	Application #	File Date	Registration #	Registration Date	Description Combined	Status
V & Green Eye Design		UNITED STATES	Seller	88/018,632	6/28/2018	5,968,324	1/21/2020	005 - Pharmaceuticals preparations and substances for the treatment of inflammation and pain; pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for post-surgical treatment of the eye	REGISTERED

Mark	Image	Country	Owner Name	Application #	File Date	Registration #	Registration Date	Description Combined	Status
AMPPLIFY		UNITED STATES	Seller	88/066,300	8/6/2018	5,951,075	12/31/2019	005 - Pharmaceutical products, namely, drug delivery agents in the form of sterile preserved ophthalmic suspension comprising mucus-penetrating nanoparticles	REGISTERED
EYSUVIS & Design BW (Eye Shaped)		UNITED STATES	Seller	88/708,748	11/27/2019	6,310,079	3/30/2021	005 - Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for the relief of the signs and symptoms of dry eye disease	REGISTERED

Mark	Image	Country	Owner Name	Application #	File Date	Registration #	Registration Date	Description Combined	Status
EYSUVIS		UNITED STATES	Seller	88/708,726	11/27/2019	6,310,078	3/30/2021	005 - Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for the relief of the signs and symptoms of dry eye disease	REGISTERED
EYSUVIS Logo Design BW		UNITED STATES	Seller	90/126,587	8/20/2020			005 - Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for the relief of the signs and symptoms of dry eye disease	ALLOWED

Mark	Image	Country	Owner Name	Application #	File Date	Registration #	Registration Date	Description Combined	Status
EYSUVIS Logo Design (Stylized) Color Logo		UNITED STATES	Seller	90/126,591	8/20/2020			005 - Pharmaceutical preparations and substances for the treatment of ophthalmological and ocular diseases and disorders; topical ophthalmic pharmaceutical preparations; topical ophthalmic pharmaceutical preparations for the relief of the signs and symptoms of dry eye disease	ALLOWED

TRADEMARK

REEL: 007773 FRAME: 0922

RECORDED: 07/08/2022